Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Guggenheim's Vamil Divan raised their price target on Jade Biosciences (NASDAQ: JBIO) by 39.1% from $23 to $32 on 2026/05/11. The analyst maintained their Strong Buy rating on the stock.

Jade Biosciences reported its Q1 2026 earnings.

Following an assessment of the print, Divan said they updated their comprehensive IgAN market model.

Earnings Report

For Q1 2026, Jade Biosciences reported:

• Loss per share of $0.57, compared to Q1 2025’s loss of $12.10.

Management did not provide EPS and revenue guidance in its press release.

CEO Tom Frohlich commented: “With the upcoming initial biomarker-rich Phase 1 data for our lead program, JADE101, and an additional program expected to enter the clinic this quarter, we are transitioning into a new phase of focused clinical execution.

“We believe these milestones position us to generate meaningful clinical insights across our portfolio over the coming quarters, while continuing to rapidly advance our pipeline of potentially best-in-class therapies for autoimmune diseases.”